This has led to the use of androgen-deprivation therapy (ADT)/AR-signaling inhibitors (ARSi) as a standard treatment regimen for prostate cancer, which is often administered in combination with chemotherapy, radiotherapy and/or immunotherapy [3]. Here, AR is linked to prostate cancer.